Important Legal Notice for Altimmune, Inc. Shareholders: Action Required by October 6, 2025
On September 25, 2025, The Gross Law Firm announced an important notice for shareholders of Altimmune, Inc. (NASDAQ: ALT). Investors who acquired shares during the specified class period are encouraged to reach out to the law firm to discuss their rights and possible actions related to their investments. The deadline for shareholders to act is October 6, 2025.
The notice specifically targets those who purchased shares between August 10, 2023, and June 25, 2025. Allegations have arisen related to the company’s public announcements concerning the results of the IMPACT Phase 2b MASH trial of Pemvidutide. On June 26, 2025, Altimmune's release revealed that the results did not meet market expectations, highlighting this significant deficiency in achieving statistical relevance regarding the primary endpoint concerned with fibrosis reduction. The Stock underwent a severe decline, dropping from $7.71 to $3.61 a share within a single day—a staggering loss of 53.2%.
Investors experiencing losses due to these developments may consider registering as lead plaintiffs in any potential class action suit against Altimmune. Notably, being appointed as a lead plaintiff is entirely voluntary, and involvement in the case may occur without the necessity of this appointment. For shareholders, the law firm provides a portfolio monitoring service designed to keep them informed of case developments throughout its lifecycle. Registration poses no cost or further obligation for participants.
The result from the IMPACT trial has raised significant concerns among investors. Initially, Altimmune had continuously set high expectations for the trial outcomes. The failing to achieve statistical significance, particularly against an unexpectedly high placebo response, has led to these notable repercussions. When asked about this significant miss, the company's executives expressed indifference about the disappointing outcomes, suggesting that they prefer to focus on future Phase 3 trial projections rather than current failures.
Shareholders are urged to promptly register for the class action, especially given the approaching deadline. Interested parties can find the necessary registration forms through the link provided by The Gross Law Firm, helping to assure they receive accurate updates related to their investment status.
The Gross Law Firm stands as an experienced legal ally for investors who have suffered losses attributed to misleading information or practices by corporations. By advocating for transparency and accountability in the business sphere, the firm aims to recover losses incurred due to misstatements made by corporate leaders, instilling investor trust and supporting proper corporate governance. They emphasize that past successes do not guarantee future results, but their dedication remains firmly in place.
For more information or to engage with The Gross Law Firm, shareholders can utilize the contact information put forth in the announcement:
The firm continues its mission to uphold investor rights and emphasize corporate integrity within financial markets. Shareholders of Altimmune, Inc. should consider their options promptly, as the window for legal action is closing on October 6, 2025.
Shareholder Information
The notice specifically targets those who purchased shares between August 10, 2023, and June 25, 2025. Allegations have arisen related to the company’s public announcements concerning the results of the IMPACT Phase 2b MASH trial of Pemvidutide. On June 26, 2025, Altimmune's release revealed that the results did not meet market expectations, highlighting this significant deficiency in achieving statistical relevance regarding the primary endpoint concerned with fibrosis reduction. The Stock underwent a severe decline, dropping from $7.71 to $3.61 a share within a single day—a staggering loss of 53.2%.
Why Contact The Gross Law Firm?
Investors experiencing losses due to these developments may consider registering as lead plaintiffs in any potential class action suit against Altimmune. Notably, being appointed as a lead plaintiff is entirely voluntary, and involvement in the case may occur without the necessity of this appointment. For shareholders, the law firm provides a portfolio monitoring service designed to keep them informed of case developments throughout its lifecycle. Registration poses no cost or further obligation for participants.
Impacts of the Trial Results
The result from the IMPACT trial has raised significant concerns among investors. Initially, Altimmune had continuously set high expectations for the trial outcomes. The failing to achieve statistical significance, particularly against an unexpectedly high placebo response, has led to these notable repercussions. When asked about this significant miss, the company's executives expressed indifference about the disappointing outcomes, suggesting that they prefer to focus on future Phase 3 trial projections rather than current failures.
Action Steps for Investors
Shareholders are urged to promptly register for the class action, especially given the approaching deadline. Interested parties can find the necessary registration forms through the link provided by The Gross Law Firm, helping to assure they receive accurate updates related to their investment status.
The Importance of Legal Representation
The Gross Law Firm stands as an experienced legal ally for investors who have suffered losses attributed to misleading information or practices by corporations. By advocating for transparency and accountability in the business sphere, the firm aims to recover losses incurred due to misstatements made by corporate leaders, instilling investor trust and supporting proper corporate governance. They emphasize that past successes do not guarantee future results, but their dedication remains firmly in place.
Contact Details
For more information or to engage with The Gross Law Firm, shareholders can utilize the contact information put forth in the announcement:
- - Address: 15 West 38th Street, 12th Floor, New York, NY 10018
- - Email: [email protected]
- - Phone: (646) 453-8903
The firm continues its mission to uphold investor rights and emphasize corporate integrity within financial markets. Shareholders of Altimmune, Inc. should consider their options promptly, as the window for legal action is closing on October 6, 2025.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.